Immunovant
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $160 | $0 | $0 |
Gross Profit | -107 | 80 | -99 | -89 |
EBITDA | -119,593 | -88,514 | -114,203 | -115,654 |
EBIT | -119,700 | -88,623 | -114,302 | -115,743 |
Net Income | -120,613 | -106,449 | -111,122 | -109,119 |
Net Change In Cash | 0 | 160 | 0 | 0 |
Free Cash Flow | -117,411 | -110,838 | -100,571 | -88,843 |
Cash | 598,912 | 713,971 | 374,685 | 472,941 |
Basic Shares | 170,872 | 151,574 | 146,922 | 146,469 |
Annual Financials
| Values in thousands | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -377 | -231 | -1,324 | -1,232 |
EBITDA | -412,572 | -269,978 | -209,627 | -155,582 |
EBIT | -412,949 | -270,209 | -210,951 | -156,814 |
Net Income | -413,840 | -259,336 | -210,960 | -156,730 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -117,505 | 93,763 | ||
Free Cash Flow | -376,633 | -214,587 | -188,390 | -106,366 |
Cash | 713,971 | 635,365 | 376,532 | 493,817 |
Basic Shares | 151,574 | 138,100 | 123,075 | 109,679 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.71 |
2025-03-31 | -$0.64 |
2024-12-31 | -$0.76 |
